全文获取类型
收费全文 | 2227559篇 |
免费 | 161285篇 |
国内免费 | 5089篇 |
专业分类
耳鼻咽喉 | 32015篇 |
儿科学 | 71418篇 |
妇产科学 | 63925篇 |
基础医学 | 317126篇 |
口腔科学 | 66368篇 |
临床医学 | 195047篇 |
内科学 | 430581篇 |
皮肤病学 | 51551篇 |
神经病学 | 178965篇 |
特种医学 | 87888篇 |
外国民族医学 | 720篇 |
外科学 | 339994篇 |
综合类 | 51111篇 |
现状与发展 | 6篇 |
一般理论 | 822篇 |
预防医学 | 163101篇 |
眼科学 | 52408篇 |
药学 | 164920篇 |
6篇 | |
中国医学 | 4682篇 |
肿瘤学 | 121279篇 |
出版年
2018年 | 22409篇 |
2017年 | 17896篇 |
2016年 | 20384篇 |
2015年 | 22318篇 |
2014年 | 30433篇 |
2013年 | 47199篇 |
2012年 | 61749篇 |
2011年 | 66049篇 |
2010年 | 39172篇 |
2009年 | 36618篇 |
2008年 | 62782篇 |
2007年 | 67609篇 |
2006年 | 68229篇 |
2005年 | 65921篇 |
2004年 | 64104篇 |
2003年 | 62195篇 |
2002年 | 60637篇 |
2001年 | 101883篇 |
2000年 | 105124篇 |
1999年 | 88026篇 |
1998年 | 24429篇 |
1997年 | 22097篇 |
1996年 | 21517篇 |
1995年 | 20429篇 |
1994年 | 19139篇 |
1992年 | 68527篇 |
1991年 | 66539篇 |
1990年 | 65567篇 |
1989年 | 63819篇 |
1988年 | 58832篇 |
1987年 | 58466篇 |
1986年 | 55414篇 |
1985年 | 53143篇 |
1984年 | 39889篇 |
1983年 | 33787篇 |
1982年 | 20422篇 |
1981年 | 18576篇 |
1979年 | 37757篇 |
1978年 | 27153篇 |
1977年 | 23469篇 |
1976年 | 21546篇 |
1975年 | 23734篇 |
1974年 | 28419篇 |
1973年 | 27451篇 |
1972年 | 25913篇 |
1971年 | 24221篇 |
1970年 | 22854篇 |
1969年 | 21762篇 |
1968年 | 20263篇 |
1967年 | 18232篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Up to now two abnormal nephrographic patterns have been described as a result of arterial hypotension as an adverse response to urographic contrast material. We would like to describe a third pattern. 相似文献
992.
Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up 总被引:1,自引:0,他引:1
A retrospective study of 232 bladder tumours with minimum follow-up 5 years is presented. The carcinoma was superficial in 66%, muscle-invasive in 31% and could not be staged in 3%. Primary treatment was mainly transurethral resection for superficial tumour, but was cystectomy or radiotherapy in 22 of 29 T1 G3. Of the superficial tumours, 71% recurred. Progression to higher T stage occurred in 15% of Ta and 29% of T1 tumours, and half of these patients died of bladder cancer. The corrected 5-year survival rates in grades 1, 2A, 2B and 3-4 were 96, 84, 64 and 43%, and in stages Ta, T1, T2 and T3 they were 94, 69, 40 and 31%. All patients with T4 tumour died within 4 years. Among the 45 patients with 40 Gy irradiation + cystectomy, the corrected 5-year survival rate was 83% in superficial and 64% in muscle-invasive tumours, and among the 38 with radical radiotherapy the rates in T1-3 were 46, 36 and 13%. Transurethral resection was successful in most Ta cases. Most T1 tumours were, like T2-4, of higher grade than Ta. Prognosis was worse in T1 than in Ta. After progression to muscle-invasive disease, even during close follow-up the outlook was poor, as poor as for patients with primary muscle-invasive disease. 相似文献
993.
994.
H Holzmann S Sollberg P Altmeyer 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》1987,38(5):253-257
A new classification of forms of progressive systemic scleroderma (PSS) is presented. Compared with previous classifications, it includes not only frequent, typical forms of PSS, but also rarer manifestations. For the first time, it considers pathogenetic factors, such as the phenomena which have become known concerning the immunological system, and distinguishes between noninflammatory and inflammatory subtypes. Etiological (in this case, immunogenetic) criteria are also considered. This classification is open to further differentiation and development. 相似文献
995.
(E)-5-(2-Bromovinyl)-2'-deoxyuridine (1; BrVUdR) inhibits the replication of herpes simplex virus type 1 (HSV-1) and of varicella-zoster virus (VZV) in vitro at concentrations of 0.01 to 0.23 mumol/l, whereas herpes simplex virus type 2 (HSV-2) is influenced only at 5.5 to 27 mumol/l. In comparison to some classical and newly developed antiherpetics, i. e. 5-iodo-2'-desoxyuridine (2; idoxuridine, IDU), 9-beta-D-arabinofuranosyladenine (4; vidarabine Ara-A), 9-(2-hydroxyethoxymethyl) guanine (5; acyclovir, ACV) and 2'-fluoro-5-iodo-1-beta-D-aracytosine (6;FIAC) the following order of decreasing activity was found:1 greater than 6 greater than 5 greater than 2 greater than 4 (against HSV-1) and 6 greater than 2 greater than 5 greater than 1 greater than 4 (against HSV-2). The high selectivity of the antiviral effect of BrVUdR towards HSV-1 and TZV is based on the fact, that proliferation of different mammalian cell lines is inhibited by 50% only at concentrations as high as 90 to 170 mumol/l, resulting in a therapeutical index of 1000 to 10,000. Successful treatment of an HSV-1 encephalitis in mice as well as an HSV-1 keratitis of rabbits confirmed the efficiency of 1 in experimental animal infections. No toxic side effects in both local and systemic applications were observed. Promising data from cell culture and animal experiments recommend 1 as a potential candidate for the local and systemic treatment of HSV-1 and VZV infections in man. 相似文献
996.
997.
A HIGH FREQUENCY OF INHERITED DEFICIENCY OF COMPLEMENT COMPONENT C4 IN DARWIN ABORIGINES 总被引:2,自引:0,他引:2
Abstract A high frequency of serum complement component C4A deficiency may explain the higher prevalence and greater severity of systemic lupus erythematosus reported in Australian Aborigines. Inherited deficiencies of serum complement components C4A, C4B, and C2 were examined in two Australian Aboriginal populations from Darwin and Alice Springs and compared with the prevalence of complement deficiencies in white Australian blood donors. The frequency of C4A deficiency alleles was 29% in Darwin Aborigines compared with 12% in Alice Springs and 17% in Canberra blood donors. Partial C4B deficiency was also higher in Darwin Aborigines than in the other populations. Inherited deficiency of serum complement component C2 was not observed. 相似文献
998.
999.
T. A. Mustoe M.D. L. B. Kaban J. B. Mulliken 《European journal of plastic surgery》1987,10(4):135-138
Summary A group of thirty children with nasal fractures was evaluated retrospectively by means of a questionnaire and hospital records. Age at the time of injury ranged from age 3 to 12 (mean = 8.6) years and mean follow-up period was 9 years. Eight patients reported some degree of nasal obstruction post reduction, but only one patient required submucous resection and two patients underwent septorhinoplasty for appearance. No patients reported class III malocclusion, or required orthodontic treatment or maxillofacial corrective surgery for maxillary hypoplasia. We concluded that a childhood nasal fracture treated by closed reduction does not have deleterious effects on facial or nasal growth.This work was supported in part by the Brigham Surgical Group Foundation, Inc., Boston, Massachusetts, USA 相似文献
1000.
F Elferink W J van der Vijgh W W ten Bokkel Huinink J B Vermorken I Klein B Winograd M K Knobf G Simonetti H E Gall J G McVie 《British journal of cancer》1987,56(4):479-483
Pharmacokinetics of the cis-platin analog ethylenediaminemalonatoplatinum(II) (JM-410) was studied in 28 cycles of 19 patients during the phase I study of this drug. The drug was administered intravenously by short-term (10-60 min) infusion. Doses ranged from 20 to 1,200mg m-2. JM-40 was determined in plasma ultrafiltrate and urine by HPLC. Platinum (Pt) concentrations were determined in plasma, plasma ultrafiltrate, urine and red blood cells by atomic absorption spectrometry up to 5 days after administration of the drug. Ultrafilterable Pt could be determined up to 45 days after the infusion in one patient sampled over such a long period. Pharmacokinetics of JM-40 showed a linear behaviour. The final half-life of total Pt in plasma was 4.1 +/- 0.9 days. The disposition of JM-40 was similar to that of ultrafilterable Pt in respect to t1/2 alpha (10 and 13 min), t1/2 beta (44 and 57 min), volumes of distribution Vc (11 and 121) and Vss (17 and 201), systemic clearance (256 and 223 ml min-1), renal clearance (69 and 73 ml min-1) and metabolic clearance (183 and 154 ml min-1). During the first 6 h 27 +/- 9% of the administered dose was excreted as JM-40. Cumulative platinum excretion in the urine amounted to 29 +/- 13% and 60 +/- 13% over the first 6 h, 24 h and 5 days, respectively. The uptake of platinum in red blood cells was limited, comprising only 0.24 +/- 0.12% of the administered dose. Although JM-40 and carboplatin are structurally closely related, pharmocokinetics and toxicity of JM-40 were more similar to cis-platin than to carboplatin. 相似文献